Sanofi (SNY) said Thursday it plans to purchase Dren Bio's experimental autoimmune treatment DR-0201 for $600 million.
The deal, which is expected to close in Q2, also includes up to $1.3 billion in milestone-based payments tied to development progress and potential product launches, the company said.
DR-0201 is a bispecific antibody meant to engage myeloid cells and remove B cells, a mechanism believed to help reset the immune system in hard-to-treat autoimmune disorders.
The drug is currently being tested in two phase 1 trials and has shown early signals of effectiveness in both lab and clinical research, Sanofi said.
The company's shares were down almost 0.5% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.